MeMed Diagnostics

Diagnostic Tools for Infectious Diseases

Health Tech & Life Sciences
Active
Series E Tirat Carmel, Israel Founded 2009
Last updated 2026-06-18
Total raised
$223.4M
Last: 2021-08
Stage
Series E
Founded
2009
Headcount
105
HQ
Tirat Carmel, Israel
Sector
Health Tech & Life Sciences

About

MeMed Diagnostics has developed and validated an immune-based protein signature, MeMed BV, which distinguishes between bacterial and viral infections, providing a powerful tool in the fight against resistant strains of bacteria. An ELISA format of MeMed BV called ImmunoXpert is cleared for use in the EU (CE-IVD), Switzerland, and Israel and is currently in pilot distribution in these areas. MeMed is also developing MeMed Key, a platform that paves the way for measuring multiple proteins and signatures, both conventional and innovative, with central lab precision at the point of care. MeMed Key will measure MeMed BV within minutes. In September 2021, the company was granted 510(k) clearance by the FDA for MeMed BV for adults and children.

Funding history · 11 rounds · $223.4M total

Q&A

What is MeMed Diagnostics' primary focus?
MeMed Diagnostics specializes in developing diagnostic tools for infectious diseases, specifically an immune-based protein signature, MeMed BV, to differentiate between bacterial and viral infections.
When was MeMed Diagnostics founded?
MeMed Diagnostics was founded in June 2009.
What was the most recent funding round for MeMed Diagnostics?
In August 2021, MeMed Diagnostics raised $93,000,000. Investors included La Maison Partners and OurCrowd.
What is the total amount of funding MeMed Diagnostics has raised to date?
MeMed Diagnostics has raised a total of $223,429,159 across all funding rounds.
How many employees does MeMed Diagnostics have?
MeMed Diagnostics has 51-200 employees.
Has MeMed Diagnostics received FDA clearance for its products?
Yes, in September 2021, MeMed Diagnostics was granted 510(k) clearance by the FDA for MeMed BV for adults and children.
What is MeMed Key?
MeMed Key is a platform being developed by MeMed Diagnostics to measure multiple proteins and signatures with central lab precision at the point of care, capable of measuring MeMed BV within minutes.
Which organizations have provided grants to MeMed Diagnostics?
MeMed Diagnostics has received grants from organizations such as EU Horizon 2020, U.S. Department of Defense, and European Innovation Council (EIC).

Team · 2

Founder · Co-founder, CTO & Chairman
LinkedIn ↗
Founder · Co-founder & CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical Decision SupportMedical DevicesDiagnostics Devices
Technologies
Artificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProviders
Business model
B2B

Highlights

1 PatentsVerified

Tags

bioconvergenceinflammatory-diseaseshealthcare-providersmedical-devicesdiagnosticsinfectious-diseaselaboratoriesimmunologypersonalized-medicineartificial-intelligencedecision-makingdigital-healthcarebacteriabioinformaticsmachine-learningbabiesclinicsearly-detectionblood-test
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)